Carbohydrate Or Derivative Thereof Attached To Or Complexed With The Agent Patents (Class 424/9.35)
  • Patent number: 11813375
    Abstract: A novel therapeutic agent for solid cancer capable of hardening the cellular tissue itself of a solid cancer to induce death or growth inhibition of cancer cells, causing solidification of the tissue, is disclosed. The therapeutic agent for solid cancer is composed of a liquid composition containing as an active component an ethoxy-containing compound capable of undergoing polycondensation in a cellular tissue. The therapeutic agent for solid cancer is capable of hardening the cellular tissue itself of a solid cancer such as lung cancer to induce death or growth inhibition of cancer cells, causing solidification of the tissue. In conventional therapeutic methods, the risk of metastasis due to spreading of cancer cells through the bloodstream cannot be eliminated. In contrast, this therapeutic agent for solid cancer instantly surrounds cancer cells, so that the risk of metastasis can be largely reduced.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: November 14, 2023
    Assignee: YANCHERS INC.
    Inventor: Junichi Shimada
  • Patent number: 11617804
    Abstract: The present invention relates to intraoperative fluorescent imaging (IFI) used both pre-clinically using in-vivo models, as well as clinically to map sentinel lymph nodes in breast cancer, skin cancer, GI cancer, lung cancer, prostate cancer and several other cancers. IFI can be used to image solid tumors both non-specifically in hepatobiliary and breast cancers as well as in prostate and ovarian cancer. In one embodiment, two-dimensional resolution to 10 ?m2 is possible with optical imaging, significantly higher than other imaging modalities. In one embodiment, the present invention relates to a series of self-assembled nanoparticles using HLA (hyaluronic acid) as both a polymeric backbone as well as targeting ligand. In some embodiments, the present invention relates to the synthesis of HLA conjugates, and the effect of variation of the hydrophobic ligand structure and conjugation level on nanoparticle self-assembly, size, ICG loading efficiency, and ICG fluorescence quenching and reactivation.
    Type: Grant
    Filed: July 18, 2015
    Date of Patent: April 4, 2023
    Assignee: WAKE FOREST UNIVERSITY
    Inventors: Aaron Michael Mohs, Tanner Kinkade Hill, Sneha Sanjay Kelkar, Steve Kridel
  • Patent number: 10646580
    Abstract: This disclosure relates to conjugates for targeting bacteria and related uses. In certain embodiments, the disclosure relates to methods of transferring a molecule of interest into bacteria comprising mixing bacteria with a non-naturally occurring conjugate under conditions such that the conjugate is transported across the bacterial cell wall. Typically, the conjugate comprises an oligosaccharide and a molecule of interest. In certain embodiments, the molecule of interest may be a tracer or an antibiotic.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: May 12, 2020
    Assignees: Emory University, Georgia Tech Research Corporation, Georgia State University Research Foundation, Inc.
    Inventors: Niren Murthy, Eric Seth Gilbert, Xinghai Ning, Mark Goodman, Bryan Stubblefield
  • Patent number: 10494423
    Abstract: The invention relates to novel cell-binding agent-cytotoxic agent conjugate having a peptide linkers and more specifically to conjugates of formula (I). The invention also provides novel cytotoxic agents of formula (II), linker compounds represented by formula (III), and drug-linker compounds represented by formula (IV). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: December 3, 2019
    Assignee: IMMUNOGEN, INC.
    Inventor: Wayne C. Widdison
  • Patent number: 9943614
    Abstract: The invention relates to diagnostic, detection, screening and imaging methods. In various embodiments, methods of diagnosis, detection, screening and imaging include administering a cationic steroid antimicrobial or CSA to a subject having or at risk of having an infection or a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in an amount effective to diagnose or detect the infection or the hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in the subject. In a particular aspect, a detectable CSA, namely CSA-13 labeled with 99mTc is used to detect the presence of an infection.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: April 17, 2018
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventor: Paul B. Savage
  • Patent number: 9884123
    Abstract: The present invention relates to ligand-targeted molecules and ligand drug conjugates (LDCs) comprising a ligand connected to a functional group, which is connected to a linker, which in turn is bonded to a drug. The LDCs of the present invention also comprise platinum coordination complex wherein the platinum is connected to the linker through monocarboxylato and O?Pt coordinate bonds. The present invention also relates to methods for preparing these ligand drug conjugates. The present invention further relates to methods for the treatment of tumours using the ligand drug conjugates of the present invention.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: February 6, 2018
    Assignee: INVICTUS ONCOLOGY PVT. LTD.
    Inventors: Shiladitya Sengupta, Sazid Hussain, Dipankar Pramanik, Monideepa Roy, Seikh Samad Hossain
  • Patent number: 9808539
    Abstract: Provided are compositions for rapid detection of lymph nodes. The compositions include magnetic particles, such as iron oxide, and a solute present in an amount that results in a hypoosomotic solution. Methods for detecting lymph nodes also are provided.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: November 7, 2017
    Assignee: ENDOMAGNETICS LTD.
    Inventors: Andrew P. Shawcross, John Gonzalez-Carvajal, Marc Brown, Rob Turner
  • Patent number: 9610367
    Abstract: There is provided an ICG-loaded polymer nanoparticle that is dynamically stable, prevents the leakage of contained ICG and the resulting discoloration, and has a high molar absorbance coefficient. The particle contains a hydrophilic dye having a sulfonate group and a hydrophobic polymer, and the particle further contains at least one of a lipid having a positively charged region, a nicotinic acid derivative and a thiamine derivative.
    Type: Grant
    Filed: August 23, 2011
    Date of Patent: April 4, 2017
    Assignee: CANON KABUSHIKI KAISHA
    Inventors: Shinzaburo Ito, Masato Minami, Tatsuki Fukui, Kouichi Kato, Fumio Yamauchi, Yoshinori Tomida, Satoshi Yuasa, Tetsuya Yano, Satoshi Ogawa, Kengo Kanazaki, Atsushi Takahashi, Daisuke Sasaguri, Hiroyuki Aoki
  • Patent number: 9421302
    Abstract: The present invention relates to a biodegradable injectable composition for bone augmentation comprising fibrin, a contrast agent and calcium salt-containing particles, as well as a method for bone augmentation in a patient suffering from a bone disorder comprising injecting said composition into a non-mineralized or hollow portion of said bone.
    Type: Grant
    Filed: April 17, 2007
    Date of Patent: August 23, 2016
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: John J. Barry, Andreas Goessl, Heinz Gulle, Monika Mangold, Melitta Bilban
  • Patent number: 9393326
    Abstract: There is provided signal modifying compositions for medical imaging comprising a carrier and signal modifying agents specific for two or more imaging modalities. The compositions are characterized by retention efficiency, with respect of the signal modifying agents that enables prolonged contrast imaging without significant depletion of the signal modifying agent from the carrier. The carriers of the present invention are lipid based or polymer based the physico-chemical properties of which can be modified to entrap or chelate different signal modifying agents and mixtures thereof and to target specific organs or tumors or tissues within a mammal.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: July 19, 2016
    Assignee: University Health Network
    Inventors: David Jaffray, Christine Allen, Jinzi Zheng, Raymond Matthew Reilly, Gregory Jason Perkins
  • Patent number: 9072782
    Abstract: Disclosed are a gadolinium complex formed by coordination of gadolinium to the diethylenetriaminepentaacetic acid dianhydride (DTPA) moiety of a pullulan-DTPA conjugate formed by an ester bond between pullulan and DTPA, a preparation method thereof, an MRI contrast composition comprising the complex, and a method of providing information for diagnosis of disease using the complex as an MRI contrast agent. The pullulan-DTPA-Gd complex has a long in vivo half-life, low toxicity, and high MRI signal intensity resulting in clear MRI images, compared to prior gadolinium complexes, indicating that it is advantageously used as an MRI contrast agent. In addition, it is possible to obtain MRI images allowing one to differentiate between diseased liver tissue and normal liver tissue, indicating that it is used as an MRI contrast agent for the liver.
    Type: Grant
    Filed: May 4, 2010
    Date of Patent: July 7, 2015
    Assignee: CATHLOIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
    Inventors: Kun Na, Hyeon A Yim
  • Publication number: 20150110721
    Abstract: A method for modulating a response signal includes introducing functionalized particles into a lumen of subsurface vasculature, wherein the functionalized particles are configured to interact with one or more target analytes present in blood circulating in the subsurface vasculature; and non-invasively detecting the one or more target analytes. A response signal, which may include a background signal and an analyte response signal related to interaction of the functionalized particles with the one or more target analytes, is transmitted from the subsurface vasculature. A modulation configured to alter the response signal such that the analyte response signal is affected differently than the background signal may be applied to a portion of subsurface vasculature. Analyte detection may be achieved by differentiating the analyte response signal from the background signal.
    Type: Application
    Filed: October 23, 2013
    Publication date: April 23, 2015
    Applicant: Google Inc.
    Inventors: Andrew Conrad, Eric Peeters, Vikram Singh Bajaj, Jason Thompson, Mark Askew
  • Patent number: 8987429
    Abstract: Disclosed herein is a GO-Gd-DTPA (gadolinium-diethylenetriamine pentaacetic-graphene oxide) complex, which is formed by an ester bond of graphene oxide (GO) and gadopentetic acid (Gd-DTPA). Since the GO-Gd-DTPA can stably exist in the body because it has high stability in water, it is expected that it can be effectively used as an MRI contrast agent.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: March 24, 2015
    Assignee: Research and Business Foundation Sungkyunkwan University
    Inventors: Hyo Young Lee, Luyang Wang
  • Publication number: 20150078995
    Abstract: A nanotheranostic probe and its use to facilitate diagnoses, treatment and targeting of amyloid deposits are disclosed herein.
    Type: Application
    Filed: September 16, 2014
    Publication date: March 19, 2015
    Inventor: Karunya K. Kandimalla
  • Patent number: 8961935
    Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent coated with carboxylated mannan, particularly a carboxylated mannan coated superparamagnetic MRI contrast agent specifically targeting antigen presenting cells and having excellent in vivo stability, and a method for producing the same. The MRI contrast agent coated with carboxylated mannan of the present invention can provide excellent in vivo stability and biocompatibility owing to its high surface negative charge, and can be introduced specifically into antigen presenting cells owing to mannose of mannan, so as to visualize the antigen presenting cells and the tissue containing the antigen presenting cells in MRI.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: February 24, 2015
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Sang Hyeon Kang, Yong Yeon Jeong, In Kyu Park, Chong Su Cho, You Kyoung Kim, Won Jong Kim, Ran Namgung
  • Publication number: 20150017098
    Abstract: The present invention relates to a carrier that is targeted at fucosylated molecule-producing cells, which comprises an effective amount of fucose for targeting said cells, to a composition comprising the carrier, and to a method for treating and diagnosing a disease related to fucosylated molecule-producing cells utilizing said carrier, etc. The carrier of the present invention enables to deliver a substance specifically to fucosylated molecule-producing cells.
    Type: Application
    Filed: October 20, 2011
    Publication date: January 15, 2015
    Inventors: Junji Kato, Rishu Takimoto
  • Patent number: 8858916
    Abstract: A compound comprising a metal chelate linked to a hexose carrier for use as a metallopharmaceutical diagnostic or therapeutic agent is provided. The compound is suitable for imaging by single-photon emission computed tomography, computer assisted tomography, magnetic resonance spectroscopy, magnetic resonance imaging, positron emission tomography, fluorescence imaging or x-ray.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: October 14, 2014
    Assignee: Mallinckrodt LLC
    Inventor: Dennis A. Moore
  • Patent number: 8852555
    Abstract: Nano-sized inorganic particles having uniform particle sizes and precisely controlled particle diameters have already been produced by synthesis in an organic solvent, but these nano-sized inorganic particles are hindered from dispersing in a polar solvent because of the adsorption of a long-chain fatty acid on the surfaces of the particles. Further, it was difficult to form nano-sized inorganic particles dispersible in a polar solvent by replacing the long-chain fatty acid coats.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: October 7, 2014
    Assignee: Tokyo Institute of Technology
    Inventors: Hiroshi Handa, Mamoru Hatakeyama, Masanori Abe, Satoshi Sakamoto, Yuka Masaike, Kosuke Nishio, Yoshinori Kita, Hiroshi Kishi
  • Publication number: 20140255307
    Abstract: The present invention relates to contrast medium composition and a method of bio imagination using the same. The contrast medium composition of the present invention includes a biomolecule, DNA nanostructure, as an active ingredient, is fundamentally non-cytotoxic and non-immunogenic and is not likely to induce safety problems that may be observed in other organic or inorganic contrast medium composition. In addition, the contrast medium composition of the present invention not only facilitates diagnosis of disease through sufficient contrast enhancement effect by showing excellent cellular uptake and intracellular stability and can visualize even SLNs which is difficult to be visualized traditionally, so can judge metastasis of cancer easily and apply lower invasive treatment.
    Type: Application
    Filed: March 5, 2014
    Publication date: September 11, 2014
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Dae Ro AHN, Se Hoon KIM
  • Publication number: 20140199235
    Abstract: The present invention relates to a nanoparticle having a linker connected to a long alkane or alkene chain, and a method for preparing the nanoparticle. The alkyl chain of C10-30 introduced with a ligand of the present invention can be coated on a hydrophobic nanoparticle through a noncovalent bond, enabling easy introduction of various ligands to the nanoparticle, and the nanoparticle having various functional groups prepared using the method can be applied to fluorescent detection, MRI, raman spectroscopy, optical detection, PET, SPECT, or gamma image device, and the ligand of the visualization agents can be modified to be used for new vessels detection, cancer cell detection, immunocyte detection, hepatocyte detection, cell death detection, and gene detection.
    Type: Application
    Filed: January 31, 2012
    Publication date: July 17, 2014
    Applicant: SNU R&DB FOUNDATION
    Inventors: Jae Min Jeong, Young Kyoung Lee, Dong Soo Lee, June-Key Chung, Myung Chul Lee
  • Publication number: 20140154185
    Abstract: A method for magnetic resonance (MR) imaging or spectroscopy on a MR scanner to detect tissue physiological parameters in one or more tissue areas in a human or non-human subject includes administering to the subject a contrast enhancing physiologically tolerable amount of a sugar that is non-labeled, subjecting the subject to an MR procedure capable of generating MR signals encoding at least one tissue area in the subject in which the sugar either passes or is taken up, detecting a temporal variation in the MR signals in the at least one tissue area after the administering the sugar, determining at least one tissue-related parameter from the temporal variation, and ascertaining whether the at least one tissue-related parameter is abnormal.
    Type: Application
    Filed: December 14, 2011
    Publication date: June 5, 2014
    Applicant: The Johns Hopkins University
    Inventors: Peter C. Van Zijl, Dmitri Artemov, Kannie Wai Yan Chan, Yoshinori Kato, Michael T. McMahon, Guanshu Liu
  • Patent number: 8729242
    Abstract: Methods for reducing the T-cell mitogenicity of lectin compositions are provided. In one aspect this is achieved by chemically modifying mitogenic lectin compositions under optimized conditions. Additionally or alternatively, the reduction in T-cell mitogenicity is achieved by removing unmodified subunits chemically modified mixtures. Modified lectin compositions with reduced T-cell mitogenicity are also provided as are uses of the inventive compositions.
    Type: Grant
    Filed: January 27, 2010
    Date of Patent: May 20, 2014
    Assignee: Smartcells, Inc.
    Inventors: Thomas M. Lancaster, Wenyi Cai, Ryan Faucette, Matthew Pecukonis, Todd C. Zion
  • Publication number: 20140099262
    Abstract: The present invention provides CDP-Choline (Citicoline) and any salt thereof comprising at least one isotopically labeled carbon atom directly bonded to at least one deuterium atom, a composition comprising said CDP-Choline, uses thereof, methods for diagnosing and evaluating a state, condition, or disease in a subject utilizing CDP-Choline of the invention and kits comprising CDP-Choline of the invention.
    Type: Application
    Filed: May 31, 2012
    Publication date: April 10, 2014
    Applicant: BRAIN WATCH LTD.
    Inventors: Rachel Katz-Brull, Moshe Gomori
  • Patent number: 8613907
    Abstract: Disclosed are compositions and methods for reducing the proliferation of cancer cells through targeted interactions with integrins.
    Type: Grant
    Filed: March 17, 2003
    Date of Patent: December 24, 2013
    Assignee: University of Rochester
    Inventors: Hartmut Land, Laurent Deleu
  • Publication number: 20130302255
    Abstract: Disclosed are novel, targeting, paramagnetic nanoparticles as contrast agent for magnetic resonance imaging. The compositions of the nanoparticles are composed of self-assembled polyelectrolyte biopolymers having targeting moieties, which can suitable for targeted delivery of paramagnetic ions complexed to the nanoparticles. The nanoparticulate contrast agent can internalize into the targeted tumor cells to realize the receptor mediated uptake, and therefore afford enhanced relaxivity and improved signal-to-noise effect on the examined tissue areas. Methods for making these targeting MRI contrast agents are also provided.
    Type: Application
    Filed: May 7, 2013
    Publication date: November 14, 2013
    Inventors: János BORBÉLY, István HAJDÚ, Magdolna BODNÁR, Ildikó SCRIFFERTNÉ DENYICSKA
  • Patent number: 8551447
    Abstract: A bifunctional compound with a monosaccharide and a N2S2 ligand, and more particularly, a bifunctional compound with a N2S2 ligand and aminohexylacetyl galactosamine (ah-GalNAc4) is provided. A method for preparing the bifunctional compound with a monosaccharide and a N2S2 ligand is also provided, including activating a carboxyl group in an organic ligand, reacting the activated carboxyl group with a galactopyranoside through amidation, and then hydrolyzing. The bifunctional compound of the present invention is widely useful in nuclear medicine for preparation of liver imaging agents for assisting in correct diagnosis of diseases.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: October 8, 2013
    Assignee: Institute of Nuclear Energy Research Atomic Energy Council, Executive Yuan
    Inventors: Show-Wen Liu, Cheng-Hsien Lin, Yu Chang, Cheng-Fang Hsu, Tsyh-Lang Lin
  • Patent number: 8545813
    Abstract: The present invention relates to contrast agents for MRI and related methods of use.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: October 1, 2013
    Assignee: Northwestern University
    Inventors: Ying Song, Thomas J. Meade, Ellen Kohlmeir
  • Patent number: 8540966
    Abstract: The present invention relates to a novel class of paramagnetic ion-based contrast agents of formula (I), wherein a chelating backbone moiety is highly functionalized by the presence of one or more polyhydroxylated chain, that show a pharmacokinetic profile analogous to that of the commonly used T1-general extravascular agents (NSA) but are further characterized by a higher relaxivity.
    Type: Grant
    Filed: June 28, 2005
    Date of Patent: September 24, 2013
    Assignee: Bracco Imaging S.p.A.
    Inventors: Silvio Aime, Matteo Galli, Luciano Lattuada, Pierfrancesco Morosini, Fulvio Uggeri, Kondareddiar Ramalingam
  • Publication number: 20130230468
    Abstract: The present invention provides isotopically labeled deoxy-glucose and derivatives thereof, methods of their preparation, ration, kits comprising them and uses thereof for spin hyperpolarized magnetic resonance imaging, utilized in the quantitative and qualitative diagnosis of states, conditions, diseases, or disorders in the body of a subject.
    Type: Application
    Filed: October 25, 2011
    Publication date: September 5, 2013
    Inventors: Moshe Gomori, Hyla Allouche-Arnon, Rachel Katz-Brull
  • Publication number: 20130101506
    Abstract: Disclosed herein are aptamers that comprise a nucleic acid sequence that has a specific affinity for a target. These aptamers can be used as delivery vehicles to deliver specific agents to particular sites. Alternatively, targeted aptamers can also be used with detection techniques to determine the presence of absence of specific targets in heterogeneous backgrounds.
    Type: Application
    Filed: September 17, 2012
    Publication date: April 25, 2013
    Inventor: Cassandra L. Smith
  • Patent number: 8420055
    Abstract: Amine functionalized magnetic nanoparticle compositions and processes for synthesizing the same are described. The process consists of obtaining a carboxylated polymer in substantially pure form, which is used to prepare a substantially size homogeneous, polymer coated carboxyl, functionalized magnetic nanoparticle. The carboxyl groups are converted to reactive primary amino groups by the use of a water-soluble carbodiimide followed by reaction of a large excess of a diamine. The amine-terminated nanoparticles are then reacted with bifunctional crosslinking agents and with various biomolecules to make nanoparticles for in vitro assays, cell sorting applications and target specific MR contrast agents.
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: April 16, 2013
    Assignee: VisEn Medical, Inc.
    Inventors: Debra A. Gaw, Lee Josephson
  • Patent number: 8377420
    Abstract: The present invention teaches a micro-porous injectable, soft elastic, fully resorbable fibrin-based composition for use as a soft tissue lumen and void filler. The composition of the present application exhibits physical characteristics, such as mechanical properties, typically seen in elastomers and mechanical stability, which is superior to fibrin alone. A variety of properties of the composition of the present invention can be effectively fine-tuned and altered by adjusting type and content of the particles as well as of the plasticizer contained in the void filler composition.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: February 19, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: John J. Barry, Andreas Goessl, Heinz Gulle, Monika Mangold, Melitta Bilban
  • Publication number: 20130022538
    Abstract: An aptamer-mRNA conjugate is provided. The aptamer-mRNA conjugate may include an aptamer component that binds a membrane associated protein on a target cell and an mRNA component that is expressed by the target cell.
    Type: Application
    Filed: June 12, 2012
    Publication date: January 24, 2013
    Inventors: John J. Rossi, Maggie Bobbin
  • Publication number: 20120276005
    Abstract: Compositions and methods for dual imaging and for dual chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns compounds comprising the structure X1—Y—X2, wherein Y comprises two or more carbohydrate residues covalently attached to one another, X1 and X2 are diagnostic or therapeutic moieties covalently attached to Y, provided that when Y does not comprise a glucosamine residue, X1 and X2 are diagnostic moieties. The present invention also concerns methods of synthesis of these compounds, application of such compounds for dual imaging and treatment of hyperproliferative disease, and kits for preparing a radiolabeled therapeutic or diagnostic compound.
    Type: Application
    Filed: April 3, 2012
    Publication date: November 1, 2012
    Inventors: David Yang, Dongfang Yu, Mithu Chanda, Ali Azhdarinia, Changsok Oh, E. Edmund Kim
  • Publication number: 20120269725
    Abstract: Method of using androgen receptor and/or butyrylcholinesterase targeted radiolabeled compounds, e.g., cycloSalingenyl pyrimidine nucleoside monophosphates, for the treatment and diagnosis of cancer.
    Type: Application
    Filed: December 23, 2010
    Publication date: October 25, 2012
    Inventors: Janine Baranowska-Kortylewicz, Zbigniew P. Kortylewicz
  • Publication number: 20120258050
    Abstract: The invention relates to a method of 13C-MR detection using an imaging medium comprising hyperpolarised 13C-fructose and to an imaging medium containing hyperpolarised 13C-fructose for use in said method.
    Type: Application
    Filed: September 8, 2010
    Publication date: October 11, 2012
    Inventors: Albert Chen, David Wilson, John Kurhanewicz, Daniel Blackburn Vigneron, Kayvan Keshari
  • Publication number: 20120230919
    Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent coated with carboxylated mannan, particularly a carboxylated mannan coated superparamagnetic MRI contrast agent specifically targeting antigen presenting cells and having excellent in vivo stability, and a method for producing the same. The MRI contrast agent coated with carboxylated mannan of the present invention can provide excellent in vivo stability and biocompatibility owing to its high surface negative charge, and can be introduced specifically into antigen presenting cells owing to mannose of mannan, so as to visualize the antigen presenting cells and the tissue containing the antigen presenting cells in MRI.
    Type: Application
    Filed: April 15, 2011
    Publication date: September 13, 2012
    Applicant: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun YOON, Soo Youn JUN, An Sung KWON, Sang Hyeon KANG, Yong Yeon JEONG, In Kyu PARK, Chong Su CHO, You Kyoung KIM, Won Jong KIM, Ran NAMGUNG
  • Publication number: 20120207684
    Abstract: A composition for imaging a cell includes a first imaging probe and a second imaging probe that include respectively a first reporter moiety and a second reporter moiety. The first reporter moiety and the second reporter moiety form a signaling complex that produces a detectable signal when the first imaging probe and second imaging probe complex with first and second biomarkers of the cell.
    Type: Application
    Filed: October 19, 2010
    Publication date: August 16, 2012
    Inventors: James Basilion, Kirti Dhingra, Thomas J. Meade, Sarah Grace Kamper
  • Publication number: 20120058054
    Abstract: Disclosed are a gadolinium complex formed by coordination of gadolinium to the diethylenetriaminepentaacetic acid dianhydride (DTPA) moiety of a pullulan-DTPA conjugate formed by an ester bond between pullulan and DTPA, a preparation method thereof, an MRI contrast composition comprising the complex, and a method of providing information for diagnosis of disease using the complex as an MRI contrast agent. The pullulan-DTPA-Gd complex has a long in vivo half-life, low toxicity, and high MRI signal intensity resulting in clear MRI images, compared to prior gadolinium complexes, indicating that it is advantageously used as an MRI contrast agent. In addition, it is possible to obtain MRI images allowing one to differentiate between diseased liver tissue and normal liver tissue, indicating that it is used as an MRI contrast agent for the liver.
    Type: Application
    Filed: May 4, 2010
    Publication date: March 8, 2012
    Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
    Inventors: Kun Na, Hyeon A Yim
  • Patent number: 8128908
    Abstract: The present invention relates to fluorescent, radio-opaque and magnetic quantum nanoparticles, useful as multifunctional contrast agents or probes for in vivo bioimaging, and methods of their use. The invention provides for multifaceted bioimaging (e.g., intra-arterial pre-operative brain mapping and broad based in vivo diagnostic imaging), including imaging of various cell types, such as stem cells.
    Type: Grant
    Filed: May 2, 2005
    Date of Patent: March 6, 2012
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Swadeshmukul Santra, Paul H. Holloway, Robert A. Mericle, Heesun Yang, Glenn A. Walter
  • Publication number: 20120045398
    Abstract: The present invention relates to the manufacture of triblock polymer ligands (30) and nanoparticle complexes (80). The nanoparticle complexes (80) comprise a capped nanoparticle (10) and the triblock polymer ligand (30). The triblock polymer ligand (30) consists of a binding polymer (40), a hydrophobic polymer (50) and a hydrophilic functionalisable polymer (60). The binding polymer (40) attaches to the capped nanoparticle (10).
    Type: Application
    Filed: September 2, 2011
    Publication date: February 23, 2012
    Inventors: Elmar Pöselt, Steffen Fischer, Stephan Förster, Horst Weller
  • Patent number: 8058413
    Abstract: The inventive molecular transporter compound shows significantly high permeability through a biological membrane such as a plasma membrane, nuclear membrane and blood-brain barrier, and accordingly, can be effectively used in delivering various biologically active molecules.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: November 15, 2011
    Assignees: Postech Foundation, Postech Academy-Industry Foundation
    Inventors: Sung-Kee Chung, Kaustabh Kumar Maiti, Woo Sirl Lee, Ock-Youm Jeon, Seok-Ho Lee
  • Patent number: 8048996
    Abstract: The inventive molecular transporter compound shows significantly high permeability through a biological membrane such as a plasma membrane, nuclear membrane and blood-brain barrier, and accordingly, can be effectively used in delivering various biologically active molecules.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: November 1, 2011
    Assignees: Postech Foundation, Postech Academy-Industry Foundation
    Inventors: Sung-Kee Chung, Kaustabh Kumar Maiti, Woo Sirl Lee, Ock-Youm Jeon, Seok-Ho Lee
  • Publication number: 20110256067
    Abstract: The present invention relates to a novel class of paramagnetic ion-based contrast agents of formula (I), wherein a chelating backbone moiety is highly functionalized by the presence of one or more polyhydroxylated chain, that show a pharmacokinetic profile analogous to that of the commonly used T1-general extravascular agents (NSA) but are further characterized by a higher relaxivity.
    Type: Application
    Filed: June 28, 2005
    Publication date: October 20, 2011
    Applicant: Bracco Imaging SpA
    Inventors: Silvio Aime, Matteo Galli, Luciano Lattuada, Pierfrancesco Morosini, Fulvio Uggeri, Kondareddiar Ramalingam
  • Publication number: 20110243857
    Abstract: A contrast agent for MRI imaging includes: (a) one cyclodextrin, whose truncated-cone-shaped structure defines a central axis, a first and a second openings along the axis, (b) one paramagnetic element, located on the cyclodextrin axis, outside the structure and proximate to the first opening, (c) one or several coordination ligand(s) of the paramagnetic element which coordinate(s) the paramagnetic element, (d) one arm covalently bound to the cyclodextrin, proximate to the second opening, which is able to form an inclusion complex with the cyclodextrin.
    Type: Application
    Filed: December 18, 2009
    Publication date: October 6, 2011
    Applicant: UNIVERSITE DE ROUEN
    Inventors: Geraldine Gouhier, Francois Estour
  • Publication number: 20110212030
    Abstract: This invention discloses a method for preparing a therapeutic or diagnostic complex comprised of a nucleic acid ligand and a lipophilic compound or non-immunogenic, high molecular weight compound by identifying a nucleic acid ligand by SELEX methodology and associating the nucleic acid ligand with a lipophilic compound or a non-immunogenic, high molecular weight compound. The invention further discloses complexes comprising one or more nucleic acid ligands in association with a lipophilic compound or non-immunogenic, high molecular weight compound.
    Type: Application
    Filed: November 23, 2009
    Publication date: September 1, 2011
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Larry Gold, Paul Schmidt, Nebojsa Janjic
  • Publication number: 20110177004
    Abstract: A compound comprising a metal chelate linked to a hexose carrier for use as a metallopharmaceutical diagnostic or therapeutic agent is provided. The compound is suitable for imaging by single-photon emission computed tomography, computer assisted tomography, magnetic resonance spectroscopy, magnetic resonance imaging, positron emission tomography, fluorescence imaging or x-ray.
    Type: Application
    Filed: September 25, 2009
    Publication date: July 21, 2011
    Inventor: Dennis A. Moore
  • Patent number: 7976825
    Abstract: Macromolecular contrast agents for magnetic resonance imaging are described. Biomolecules and their modified derivatives form stable complexes with paramagnetic ions thus increasing the molecular relaxivity of carriers. The synthesis of biomolecular based nanodevices for targeted delivery of MRI contrast agents are described. Nanoparticles (NP) have been constructed by self-assembling of chitosan (CHIT) as polycation and poly-gamma glutamic acids (PGA) as polyanion. NP's are capable of Gd-ion uptake forming a particle with suitable molecular relaxivity. Folic acid (FA) is linked to the NP's to produce NP-FA bioconjugates that can be used for targeted in vitro delivery to a human cancer cell line.
    Type: Grant
    Filed: December 8, 2008
    Date of Patent: July 12, 2011
    Inventors: Janos Borbely, Magdolna Bodnar, John F Hartmann, Istvan Hajdu, Jozsef Kollar, Gyorgy Vamosi
  • Patent number: 7973084
    Abstract: The inventive molecular transporter compound shows significantly high permeability through a biological membrane such as plasma membrane, nuclear membrane and blood-brain barrier, and accordingly, it can be effectively used in delivering various biologically active molecules, such as doxorubicin and paclitaxel to target cells.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: July 5, 2011
    Assignee: Postech Academy-Industrial Foundation
    Inventors: Sung-Kee Chung, Woo Sirl Lee, Kaustabh Kumar Maiti
  • Publication number: 20110123457
    Abstract: A therapeutic agent formed of a magnetic resonance imaging tracer conjugated with a chemotherapeutic agent. The therapeutic agents can be used in measuring drug delivery to a target tissue. The therapeutic agents allow for therapeutic MRI, in which 19F MRI techniques are used to detect, monitor, evaluate, and/or adjust chemotherapeutic drug dosage levels in a patient or a targeted tissue thereof.
    Type: Application
    Filed: December 17, 2010
    Publication date: May 26, 2011
    Inventor: Yihua Yu